Korean Journal of Anesthesiology

The Korean Society of Anesthesiologists (대한마취통증의학회)
권호 표지
DOI QR코드

DOI QR Code

Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia

  • Yoo, Jae Hwa (Department of Anesthesiology and Pain Medicine, Soonchunhyang University Seoul Hospital) ;
  • Kim, Soon Im (Department of Anesthesiology and Pain Medicine, Soonchunhyang University Seoul Hospital) ;
  • Chung, Ji Won (Department of Anesthesiology and Pain Medicine, Soonchunhyang University Seoul Hospital) ;
  • Jun, Mi Roung (Department of Anesthesiology and Pain Medicine, Soonchunhyang University Seoul Hospital) ;
  • Han, Yoo Mi (Department of Anesthesiology and Pain Medicine, Soonchunhyang University Seoul Hospital) ;
  • Kim, Yong Jik (Department of Anesthesiology and Pain Medicine, Soonchunhyang University Seoul Hospital)
  • Received : 2018.01.12
  • Accepted : 2018.04.28
  • Published : 2018.12.01
⟨ Previous Next ⟩

Abstract

Background: The aim of this study was to evaluate aprepitant in combination with palonosetron as compared to palonosetron alone for the prevention of postoperative nausea and vomiting (PONV) in female patients receiving fentanyl-based intravenous patient-controlled analgesia (IV-PCA). Methods: In this randomized single-blinded study, 100 female patients scheduled for elective surgery under general anesthesia were randomized to two groups: Group AP (80 mg aprepitant plus 0.075 mg palonosetron, n = 50) and Group P (0.075 mg palonosetron, n = 50). The patients in group AP received 80 mg aprepitant per oral 1-3 h before surgery, while all patients received 0.075 mg palonosetron after induction of standardized anesthesia. All patients had postoperative access to fentanyl-based IV-PCA. The incidence of nausea and vomiting, use of rescue medication, and severity of nausea were evaluated at 6 and 24 h after surgery. Results: The incidence of nausea (54%) and vomiting (2%) in group AP did not differ significantly from that in group P (48% and 14%, respectively) during the first 24 h after surgery (P > 0.05). Patient requirements for rescue medication in group AP (29%) were similar to those in group P (32%) at 24 h after surgery (P > 0.05). There was no difference between the groups in severity of nausea during the first 24 h after surgery (P > 0.05). Conclusions: Aprepitant combined with palonosetron did not reduce the incidence of PONV as compared to palonosetron alone within 24 h of surgery in women receiving fentanyl-based IV-PCA.

Keywords

Acknowledgement

Supported by : Soonchunhyang University

References

  1. Gan TJ, Diemunsch P, Habib AS, Kovac A, Kranke P, Meyer TA, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2014; 118: 85-113. https://doi.org/10.1213/ANE.0000000000000002
  2. Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 1992; 77: 162-84. https://doi.org/10.1097/00000542-199207000-00023
  3. Diemunsch P, Joshi GP, Brichant JF. Neurokinin-1 receptor antagonists in the prevention of postoperative nausea and vomiting. Br J Anaesth 2009; 103: 7-13. https://doi.org/10.1093/bja/aep125
  4. Ho KY, Gan TJ. Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Curr Opin Anaesthesiol 2006; 19: 606-11. https://doi.org/10.1097/01.aco.0000247340.61815.38
  5. Rojas C, Thomas AG, Alt J, Stathis M, Zhang J, Rubenstein EB, et al. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 2010; 626: 193-9. https://doi.org/10.1016/j.ejphar.2009.10.002
  6. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, et al. Palonosetron improves prevention of chemotherapyinduced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-7. https://doi.org/10.1093/annonc/mdg417
  7. Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98: 2473-82. https://doi.org/10.1002/cncr.11817
  8. Rojas C, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J, et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 2008; 107: 469-78. https://doi.org/10.1213/ane.0b013e318172fa74
  9. Chun HR, Jeon IS, Park SY, Lee SJ, Kang SH, Kim SI. Efficacy of palonosetron for the prevention of postoperative nausea and vomiting: a randomized, double-blinded, placebo-controlled trial. Br J Anaesth 2014; 112: 485-90. https://doi.org/10.1093/bja/aet340
  10. Candiotti KA, Kovac AL, Melson TI, Clerici G, Joo Gan T. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting. Anesth Analg 2008; 107: 445-51. https://doi.org/10.1213/ane.0b013e31817b5ebb
  11. Kovac AL, Eberhart L, Kotarski J, Clerici G, Apfel C. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period. Anesth Analg 2008; 107: 439-44. https://doi.org/10.1213/ane.0b013e31817abcd3
  12. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112-9. https://doi.org/10.1200/JCO.2003.01.095
  13. Rojas C, Raje M, Tsukamoto T, Slusher BS. Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Eur J Pharmacol 2014; 722: 26-37. https://doi.org/10.1016/j.ejphar.2013.08.049
  14. Hesketh PJ, Bohlke K, Lyman GH, Basch E, Chesney M, Clark-Snow RA, et al. Antiemetics: American society of clinical oncology focused guideline update. J Clin Oncol 2016; 34: 381-6.
  15. Diemunsch P, Gan TJ, Philip BK, Girao MJ, Eberhart L, Irwin MG, et al. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery. Br J Anaesth 2007; 99: 202-11. https://doi.org/10.1093/bja/aem133
  16. Gan TJ, Apfel CC, Kovac A, Philip BK, Singla N, Minkowitz H, et al. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg 2007; 104: 1082-9. https://doi.org/10.1213/01.ane.0000263277.35140.a3
  17. Diemunsch P, Apfel C, Gan TJ, Candiotti K, Philip BK, Chelly J, et al. Preventing postoperative nausea and vomiting: post hoc analysis of pooled data from two randomized active-controlled trials of aprepitant. Curr Med Res Opin 2007; 23: 2559-65. https://doi.org/10.1185/030079907X233115
  18. Lee SJ, Lee SM, Kim SI, Ok SY, Kim SH, Park SY, et al. The effect of aprepitant for the prevention of postoperative nausea and vomiting in patients undergoing gynecologic surgery with intravenous patient controlled analgesia using fentanyl: aprepitant plus ramosetron vs ramosetron alone. Korean J Anesthesiol 2012; 63: 221-6. https://doi.org/10.4097/kjae.2012.63.3.221
  19. Apfel CC, Laara E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999; 91: 693-700. https://doi.org/10.1097/00000542-199909000-00022
  20. Apfel CC, Korttila K, Abdalla M, Kerger H, Turan A, Vedder I, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med 2004; 350: 2441-51. https://doi.org/10.1056/NEJMoa032196
  21. Habib AS, El-Moalem HE, Gan TJ. The efficacy of the 5-HT3 receptor antagonists combined with droperidol for PONV prophylaxis is similar to their combination with dexamethasone. A meta-analysis of randomized controlled trials. Can J Anaesth 2004; 51: 311-9. https://doi.org/10.1007/BF03018234
  22. Vallejo MC, Phelps AL, Ibinson JW, Barnes LR, Milord PJ, Romeo RC, et al. Aprepitant plus ondansetron compared with ondansetron alone in reducing postoperative nausea and vomiting in ambulatory patients undergoing plastic surgery. Plast Reconstr Surg 2012; 129: 519-26. https://doi.org/10.1097/PRS.0b013e31822b6932
  23. Trimas SJ, Trimas MD. Use of aprepitant and factors associated with incidence of postoperative nausea and vomiting in patients undergoing facial plastic surgery. JAMA Facial Plast Surg 2015; 17: 251-5. https://doi.org/10.1001/jamafacial.2015.0307
  24. Stathis M, Pietra C, Rojas C, Slusher BS. Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol 2012; 689: 25-30. https://doi.org/10.1016/j.ejphar.2012.05.037
  25. Thomas AG, Stathis M, Rojas C, Slusher BS. Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells. Exp Brain Res 2014; 232: 2637-44. https://doi.org/10.1007/s00221-014-4017-7
  26. Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 2014; 25: 1328-33. https://doi.org/10.1093/annonc/mdu101
  27. Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 2014; 25: 1340-6. https://doi.org/10.1093/annonc/mdu110
  28. Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 2003; 39: 1074-80. https://doi.org/10.1016/S0959-8049(02)00674-3

Cited by

  1. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting vol.131, pp.2, 2018, https://doi.org/10.1213/ane.0000000000004833
  2. Prevention and Treatment of Postoperative Nausea and Vomiting (PONV): A Review of Current Recommendations and Emerging Therapies vol.16, pp.None, 2018, https://doi.org/10.2147/tcrm.s256234
  3. Management strategies for the treatment and prevention of postoperative/postdischarge nausea and vomiting: an updated review vol.9, pp.None, 2018, https://doi.org/10.12688/f1000research.21832.1
  4. Neurokinin-1 Antagonists for Postoperative Nausea and Vomiting vol.81, pp.10, 2021, https://doi.org/10.1007/s40265-021-01532-y